Allarity Therapeutics (NASDAQ:ALLR) Trading 2.7% Higher – What’s Next?

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was up 2.7% during mid-day trading on Wednesday . The company traded as high as $1.1850 and last traded at $1.16. 162,153 shares were traded during mid-day trading, an increase of 5% from the average daily volume of 154,370 shares. The stock had previously closed at $1.13.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wall Street Zen upgraded shares of Allarity Therapeutics to a “hold” rating in a research note on Saturday, May 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Monday, April 20th. Finally, Ascendiant Capital Markets lifted their target price on Allarity Therapeutics from $9.75 to $10.25 and gave the stock a “buy” rating in a report on Monday, June 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Allarity Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $10.25.

Allarity Therapeutics Trading Up 2.7%

The firm’s 50-day moving average price is $1.47 and its 200-day moving average price is $1.23. The stock has a market capitalization of $18.46 million, a PE ratio of -1.61 and a beta of 0.53.

Allarity Therapeutics (NASDAQ:ALLR) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.05. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. On average, equities research analysts predict that Allarity Therapeutics, Inc. will post -0.92 earnings per share for the current fiscal year.

Institutional Trading of Allarity Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in Allarity Therapeutics during the 2nd quarter valued at $27,000. XTX Topco Ltd purchased a new position in Allarity Therapeutics during the fourth quarter worth $36,000. Geode Capital Management LLC boosted its stake in Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after buying an additional 16,729 shares during the period. Citadel Advisors LLC bought a new position in Allarity Therapeutics during the third quarter valued at $149,000. Finally, Capital Advisors Inc. OK bought a new position in Allarity Therapeutics during the fourth quarter valued at $108,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.